← Back to Search

Melatonin Receptor Agonist

Melatonin for Huntington's Disease

N/A

Waitlist Available

Led By Erin Furr Stimming, MD

Research Sponsored by The University of Texas Health Science Center, Houston

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline, week 5, week 9

Summary

This trial is testing if taking melatonin can help people with the Huntington's Disease gene sleep better. Melatonin has been studied for its potential to improve sleep in various populations, including those with sleep disorders and neurodegenerative conditions.

Eligible Conditions

Huntington's Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline, week 5, week 9

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline, week 5, week 9

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 5, week 9 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in sleep quality, as assessed by the Pittsburgh Sleep Quality Index (PSQI)

Secondary study objectives

Improvement in daytime somnolence, as evaluated by the Epworth Sleepiness Scale (ESS)

Improvement in global cognitive functioning, as assessed by the Montreal cognitive assessment (MoCA)

Improvement in quality of life, as evaluated by the Huntington's Disease Quality of Life Questionnaire (HDQoL)

+2 more

Side effects data

From 2014 Phase 2 trial • 40 Patients • NCT01114373

42%

Fatigue

39%

Early Morning Wakening

36%

Daytime drowsiness

11%

Weakness

11%

Dizziness

11%

Nausea

11%

Blurred vision

100%

80%

60%

40%

20%

Study treatment Arm

Melatonin

Placebo

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: MelatoninExperimental Treatment1 Intervention

Group II: PlaceboPlacebo Group1 Intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Melatonin

2014

Completed Phase 4

~1150

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor

946 Previous Clinical Trials

344,570 Total Patients Enrolled

Huntington's Disease Society of AmericaUNKNOWN

1 Previous Clinical Trials

60 Total Patients Enrolled

Erin Furr Stimming, MD5.09 ReviewsPrincipal Investigator - The University of Texas Health Science Center, Houston

The University of Texas Health Science Center, Houston

5Patient Review

Dr. Furr-Stimming is one of the most compassionate people I have ever had the pleasure of meeting, let alone receiving care from. They answered all of my questions thoroughly and with the patience of a saint.